Genomic and Clinical Features Associated with Reduced Susceptibility to Cefiderocol and Cross-resistance to β-lactam/β-lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa
Clicks: 1
ID: 313431
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #390 of 431 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 431 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Cefiderocol retains high rates of activity against carbapenem-resistant P. aeruginosa (CRPA) and is being introduced as a last resort antibiotic in developing countries. This study assessed the clinical and genotypic characteristics associated with decreased cefiderocol susceptibility among a global collection of CRPA isolates. METHODS: Clinical isolates (n=186) selected from 972 patients enrolled from 10 countries as part of the Prospective Observational Pseudomonas (POP) study were characterized by whole-genome sequencing, cefiderocol broth microdilution, and population analysis profile. We compared clinical and genomic characteristics between susceptible isolates and those with reduced cefiderocol susceptibility (defined as heteroresistant by population analysis, or intermediate or resistant using current breakpoints). A hollow fiber infection model was used to evaluate the emergence of resistance under human serum simulated cefiderocol exposures. RESULTS: Of the 186 isolates, 11 (5.9%) were cefiderocol non-susceptible and 28 (15.1%) were heteroresistant using CLSI breakpoints. With EUCAST breakpoints, 20 (10.8%) were cefiderocol resistant and 20 (10.8%) were heteroresistant. Reduced susceptibility isolates were present across all geographic regions and harbored changes in PirRS-regulated siderophore receptors, AmpC β-lactamase mutations associated with decreased ceftolozane/tazobactam susceptibility, cpxS mutations, and the β-lactamases blaNDM and blaVEB. Resistance to ceftolozane/tazobactam and ceftazidime/avibactam were independently associated with reduced cefiderocol susceptibility. Cefiderocol resistance emerged in a heteroresistant, but not susceptible isolate at human simulated exposures. CONCLUSIONS: Decreased cefiderocol susceptibility is present worldwide and is not restricted to a clonal high-risk lineage. This raises concerns about the use of cefiderocol as a salvage regimen in patients with multidrug-resistant P. aeruginosa infection.
| Reference Key |
openalex_W7161396011
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Stephanie L Egge, Donghoon Kang, Nazanin Pouya, Philip C Thornton, Erika Flores, Karim Clarke, Max W Adelman, Cornelius Rosenbaum, Rodrigo Baptista, Cesar A Arias, Vincent H. Tam, Michael J Satlin, William R Miller |
| Journal | The Journal of infectious diseases |
| Year | 2026 |
| DOI |
10.1093/infdis/jiag263
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.